MDxHealth SA
MDXH
查看详细走势图
3.335USD
+0.185+5.87%
交易中 （美东）报价延迟15分钟
165.07M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.87%
5天
+0.45%
1月
+0.45%
6月
+68.18%
今年开始到现在
+40.72%
1年
+47.57%
查看详细走势图
TradingKey MDxHealth SA股票评分
单位: USD 更新时间: 2025-12-19操作建议
MDxHealth SA当前公司基本面数据相对稳定，增长潜力很大。当前估值低估，在生物技术与医疗研究行业排名99/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价7.04。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
MDxHealth SA评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
强力买入
评级
6.040
目标均价
+325.35%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
MDxHealth SA亮点
亮点风险
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
业绩高增长
公司营业收入稳步增长，连续3年增长143.02%
业绩增长期
公司处于发展阶段，最新年度总收入90.05M美元
估值合理
公司最新PE估值-3.16，处于3年历史合理位
机构减仓
最新机构持股21.80M股，环比减少9.10%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值202.80K
活跃度增加
近期活跃度增加，过去20天平均换手率0.58
MDxHealth SA新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
MDxHealth SA简介
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
公司代码MDXH
公司MDxHealth SA
CEOMr. Michael K. McGarrity
网址https://mdxhealth.com/
常见问题
MDxHealth SA(MDXH)的当前股价是多少？
MDxHealth SA(MDXH)的当前股价是 3.335。
MDxHealth SA的股票代码是什么？
MDxHealth SA的股票代码是MDXH。
MDxHealth SA股票的52周最高点是多少？
MDxHealth SA股票的52周最高点是--。
MDxHealth SA股票的52周最低点是多少？
MDxHealth SA股票的52周最低点是--。
MDxHealth SA的市值是多少？
MDxHealth SA的市值是165.07M。
MDxHealth SA的净利润是多少？
MDxHealth SA的净利润为-38.07M。
现在MDxHealth SA(MDXH)的股票是买入、持有还是卖出？
根据分析师评级，MDxHealth SA(MDXH)的总体评级为--，目标价格为6.040。
MDxHealth SA(MDXH)股票的每股收益（EPS TTM）是多少
MDxHealth SA(MDXH)股票的每股收益（EPS TTM）是-0.998。
相关品种
